📰 Full Story
On April 18, 2026, President Donald Trump signed an executive order directing federal agencies to accelerate research, review and potential patient access to psychedelic drugs, with particular focus on ibogaine.
The order instructs the Food and Drug Administration to expedite reviews — including adding three psychedelics to a National Priority Voucher pilot — and opens a pathway under the federal Right to Try law for desperately ill patients.
The White House announced a $50 million federal research commitment for ibogaine, supplementing $50 million pledged by Texas, and said agencies will streamline clinical-trial guidance and data-sharing with the Department of Veterans Affairs.
Administration officials and allies at the Oval Office event included Health Secretary Robert F. Kennedy Jr., FDA Commissioner Marty Makary and veteran advocates; podcaster Joe Rogan also attended.
Ibogaine remains a Schedule I substance in the United States and carries known cardiac risks; supporters point to small studies, including Stanford research, that reported symptom improvements for PTSD and addiction.
Officials said faster decisions could come within months but emphasized trials and safety protocols would continue to be required.







💬 Commentary